logo
Dentist was previously on probation before treating 9-year-old girl who died after anesthesia

Dentist was previously on probation before treating 9-year-old girl who died after anesthesia

Fox News4 hours ago

A California dentist who treated a 9-year-old girl hours before she died following a routine procedure was placed on probation years prior for another procedure mishap, documents show.
Back in 2020, Dr. Ryan Watkins was disciplined over a 2016 incident in which a 54-year-old man's heart stopped after Watkins put him under anesthesia during a dental procedure.
According to a complaint filed with the Dental Board of California, Watkins engaged in "unprofessional conduct" after "clearly excessively administering drugs or treatment" to the patient, identified only as "MK."
The man had seen Watkins approximately three times before the dental surgery and was considered to be in "excellent health" and was a triathlete.
However, it was noted that the victim had a low resting heart rate, dental phobia and had a history of fainting, which the complaint said Watkins did not investigate or document.
The patient's heart stopped during the surgery where Watkins began CPR to revitalize it until EMS arrived, the documents said.
Hospital staff noted that the victim's ribs were fractured due to Watkins performing chest compressions on him. The man was later diagnosed with a mild neurocognitive disorder caused by cardiac arrest, records show.
"A doctor concluded that the administration of ephedrine likely caused MK's tachycardia (increased heart rate above 100 bpm) that would have subsided and that the use of adenosine was unnecessary and caused MK's heart to stop (asystole)," the documents read.
Watkins was placed under probation for 35 months by the California Dental Board, which still allowed him to keep working at the practice as long as he complied with additional requirements and oversight.
According to the decision, Watkins was also ordered to pay more than $19,000 to cover investigative and prosecution costs.
Watkins confirmed the previous incident to Fox News Digital, stating that "emergency protocols were immediately activated" once the patient developed cardiac arrhythmia during the procedure.
"Following this incident, regulatory proceedings were initiated. Throughout this process, we maintained that comprehensive safety protocols were followed, all medications were administered according to manufacturer guidelines based on the patient's age and weight, and the patient received continuous monitoring," Watkins explained in a statement.
He added that "in an effort to resolve the matter and focus on patient care," a settlement was reached without admission of wrongdoing and probation orders were completed.
"This experience has reinforced our unwavering commitment to patient safety. We continue to maintain rigorous adherence to established emergency response procedures, comprehensive safety protocols, and continuous patient monitoring systems to ensure the highest standard of care for all our patients."
Watkins is still practicing at Dreamtime Dentistry and reiterated that he was not at fault for 9-year-old Silvanna Moreno's death and not aware of her health issues.
"The coroner's report showed her death to be an accident due to a pre-existing medical condition of which none of the parties were aware prior to the procedure," the statement from Watkins read.
"While the Medical Examiner has ruled this an accident, we take this outcome with the utmost seriousness," the statement continued.
Watkins added that a thorough internal review of Moreno's case is being conducted and that they are consulting with leading experts in dental anesthesia to ensure patient safety is provided.
"The safety and well-being of our patients will always remain our highest priority. We are committed to learning from this tragic event and will implement any additional safety measures that may help prevent such occurrences in the future," Watkins said.
Moreno had been referred to the practice for dental treatment under general anesthesia "due to her young age and situational anxiety," on March 18, where she was seen by Watkins, according to a previous statement obtained by Fox News Digital.
Watkins said that "the dosage administered was appropriate for the patient's age and weight, following established medical protocols."
"Any interactions or negative side effects were not due to dosage but instead due to her rare but undiagnosed/undetected medical condition," Watkins shared in a statement with Fox News Digital.
According to an autopsy report from the San Diego County Medical Examiner's Office, authorities ruled that her manner of death was an accident caused by "methemoglobinemia in the setting of recent nitrous oxide administration."
"We are profoundly saddened by the tragic loss of Silvanna Moreno, and our hearts continue to go out to her family during this incredibly difficult time," Watkins said.
Stepheny Price is a writer for Fox News Digital and Fox Business. She covers topics including missing persons, homicides, national crime cases, illegal immigration, and more. Story tips and ideas can be sent to stepheny.price@fox.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Is UNH's Dividend at Risk Due to Its Falling Stock Price?
Is UNH's Dividend at Risk Due to Its Falling Stock Price?

Yahoo

time44 minutes ago

  • Yahoo

Is UNH's Dividend at Risk Due to Its Falling Stock Price?

UnitedHealth Group Incorporated (NYSE:UNH) is one of the . UnitedHealth Group Incorporated (NYSE:UNH) is currently facing some challenges in terms of stock price. The stock has fallen sharply, down 39% since the beginning of 2025 and over 37% in the past 12 months. That's a steep drop for such a major company. However, despite the decline, its market value remains strong, keeping it among the world's largest healthcare firms. A senior healthcare professional giving advice to a patient in a clinic. As a result of the lower share price, UnitedHealth Group Incorporated (NYSE:UNH)'s dividend yield has risen to 2.87%. A falling stock price can increase a stock's dividend yield, but that doesn't necessarily mean the dividend is in danger. To judge dividend safety, it's important to look at a company's financials, especially the payout ratio and free cash flow. UnitedHealth Group Incorporated (NYSE:UNH)'s payout ratio stands at a manageable 35%, suggesting it retains enough earnings to reinvest in the business or cushion against downturns. The company also generated $24.9 billion in free cash flow over the past 12 months, while paying just $7.7 billion in dividends. This indicates its dividend remains well-supported as long as business performance stays stable. In addition, UnitedHealth Group Incorporated (NYSE:UNH) has raised its payouts consistently every year since 2011. This makes UNH one of the best next generation dividend aristocrat stocks. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.

Federal judge rules Tump directives canceling NIH grants are 'void,' 'illegal'
Federal judge rules Tump directives canceling NIH grants are 'void,' 'illegal'

Yahoo

timean hour ago

  • Yahoo

Federal judge rules Tump directives canceling NIH grants are 'void,' 'illegal'

A federal judge in Massachusetts ruled on Monday that directives from the Trump administration that led to the cancellations of several research grants from the National Institutes of Health (NIH) were "void" and "illegal." U.S. District Judge William Young said the cancellation of the grants -- related to studies involving LGBTQ+ issues, gender identity and diversity, equity and inclusion (DEI) -- violated federal law, saying it was a case of racial discrimination and discrimination against the LGBTQ+ community, according to the plaintiffs in the case. Two lawsuits had been filed against the administration: One led by the American Public Health Association and the other filed by a group of 16 states. Some estimates have suggested that up to $1.8 billion in research funding had been cut. MORE: NIH terminating active research grants related to LGBTQ+, DEI studies Young, an appointee of President Ronald Reagan, said he was ordering the NIH to restore the grants that were terminated. In a statement, Andrew Nixon, the director of communications for the Department of Health and Human Services, said the agency stands by its decision to end funding for research "that prioritized ideological agendas over scientific rigor and meaningful outcomes for the American people. Under the leadership of Secretary Kennedy and the Trump administration, HHS is committed to ensuring that taxpayer dollars support programs rooted in evidence-based practices and gold standard science – not driven by divisive DEI mandates or gender ideology." Nixon said HHS is "exploring all legal options, including filing an appeal and moving to stay the order." Among the plaintiffs is Dr. Brittany Charlton, an associate professor at Harvard T.H. Chan School of Public Health, who had all her grants terminated by the NIH. One of the terminated grants focused on documenting obstetrical outcomes for lesbian, gay and bisexual women and another focused on how discriminatory laws impact mental health among LGBTQ+ teens. "As a plaintiff, I felt truly seen -- it was a rare moment when the deep harm caused to researchers and the communities we serve was acknowledged out loud, in front of the world," Charlton told ABC News in a statement. "Sitting there, I felt a wave of relief and hope as the judge condemned the government's actions and ordered the grants to be reinstated," the statement continued. "After so much uncertainty and disruption, it finally felt like justice and the value of our research -- and the communities at its heart -- were being affirmed." The terminations came after President Donald Trump passed a flurry of executive orders including vowing to "defend women from gender ideology extremism" and aiming to dismantle DEI initiatives. MORE: Judge blocks Trump administration's move to cut billions in NIH scientific funding According to termination letters sent to researchers at various universities that were reviewed by ABC News, the administration said the canceled projects do not serve the "priorities" of the current administration. "Research programs based on gender identity are often unscientific, have little identifiable return on investment, and do nothing to enhance the health of many Americans. Many such studies ignore, rather than seriously examine, biological realities. It is the policy of NIH not to prioritize these research programs," some of the termination letters read. "The premise…is incompatible with agency priorities, and no modification of the project could align the project with agency priorities," the letters continued. ABC News' Sony Salzman contributed to this report. Federal judge rules Tump directives canceling NIH grants are 'void,' 'illegal' originally appeared on

Amazfit Expands Active 2 Lineup with the New Active 2 Square — All the Same Features, Now in a Sleek Square Design
Amazfit Expands Active 2 Lineup with the New Active 2 Square — All the Same Features, Now in a Sleek Square Design

Yahoo

timean hour ago

  • Yahoo

Amazfit Expands Active 2 Lineup with the New Active 2 Square — All the Same Features, Now in a Sleek Square Design

MILPITAS, Calif., June 17, 2025--(BUSINESS WIRE)--Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), a health technology company, today announced the launch of the square version of the Amazfit Active 2, a new addition to its fitness smartwatch line that offers the same powerful features and premium experience as the recently launched round Active 2 — now in a modern, square form factor. Same Features. New Shape. Debuting at CES 2025 and featured at Pepcom and ShowStoppers, the Active 2 Square is designed for consumers who prefer a bold, geometric aesthetic without compromising performance, durability, or advanced health and fitness tracking. Featuring a square, 1.75 inch sapphire glass high-definition AMOLED display elegantly encased in a polished stainless-steel frame, the Amazfit Active 2 delivers an optimal visual experience with a peak brightness of 2,000 nits, ensuring clarity even in bright light. The graceful metal finish adds a sophisticated touch, perfectly complementing modern, style-conscious lifestyles. Its distinctive geometric form reflects a unique design identity and its intuitive interface and expansive viewing surface provide seamless access to health metrics, messages, and workouts. The device retains the full suite of features that made the round Active 2 a standout. Product Specs Latest Generation Biosensor: The BioTracker™ 6.0 PPG biosensor features a dual-LED and 5PD build, which picks up more biometric signals for enhanced precision in health monitoring and measurement. Upgraded Heart Rate and Sleep Algorithms: The PulsePrecision™ algorithm enhances heart rate tracking accuracy to the level of the Amazfit T-Rex 3, while the RestoreIQ™ algorithm gives sleep monitoring a similar accuracy boost. Additional Sensors: Compared to the previous generation of Amazfit Active, the new release adds a barometer for accurate altitude measurements and support of new sports like skiing, along with an accelerometer and gyroscope for precise recognition of sleep and movement, and an ambient light sensor for optimal display under varying light conditions. Extended Battery Life: With a robust 10-day battery life under typical use, the Active 2 Square is a device that won't need recharging every night. Zepp Flow™: Enables users to control their watch settings, adjust their calendar, and more with just their voice, while also granting Android users the ability to reply to instant messages with either keyboard or speech-to-text input. Fitness and Wellness Features Dynamic Fitness Modes: Over 160 sports modes including official HYROX Race Mode, a smart Strength Training mode that can auto-detect specific exercises and intelligently count reps, sets, and rest time, and new winter sports like Skiing. Offline Maps with Turn Directions: Supported by 5 satellite systems, users can navigate with ease by importing offline maps and route files to the watch that come with turn-by-turn directions, which can be followed on-screen or broadcast via the built-in speaker or the user's connected Bluetooth headphones. Zepp Coach™ Integration: Offers personalized training and running plans, empowering users of all levels to achieve fitness milestones from 3K runs to full marathons. Tailored for Women: With the mini app, women can connect to their accounts directly from the watch for personalized wellness insights tied to their menstrual and hormonal cycles. Advanced Health Insights: A daily Readiness score summarizes mental and physical recovery and provides actionable insights, while the HRV feature delivers specialized recovery data. Availability and Pricing The Amazfit Active 2 Square is available for purchase beginning today on and Amazon. Priced at $149.99 USD or €149.90 euro, the Active 2 Square delivers premium features and performance at an unbeatable value. For more information, please visit and follow us on Facebook, Instagram, X (formerly Twitter) and YouTube. About Amazfit Amazfit, a leading global smart wearable brand focused on health and fitness, is part of Zepp Health (NYSE: ZEPP), a health technology company with its principal office based in Gorinchem, the Netherlands. Zepp Health operates as a distributed organization, with team members and offices across the Americas, Europe, Asia, and other global markets. Offering a wide selection of smartwatches and bands, Amazfit's brand tagline, "Discover Amazing," encourages individuals to break barriers, exceed expectations, and find joy in every moment. Amazfit is powered by Zepp Health's proprietary health management platform, which delivers cloud-based, 24/7 actionable insights and guidance to help users achieve their wellness goals. Known for outstanding craftsmanship, Amazfit smartwatches have won numerous design awards, including the iF Design Award and the Red Dot Design Award. Launched in 2015, Amazfit is embraced by millions of users, with products available in over 90 countries across the Americas, EMEA, and APAC regions. For more information, visit View source version on Contacts Media Contact Mary Thompson WoodburyHead of PR, North

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store